Chimerix (CMRX) Reports In-Line Q1 EPS, Announces Strategy Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts CMRX Hot Sheet
Join SI Premium – FREE
Chimerix (NASDAQ: CMRX) reported Q1 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.5 million.
- Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission
- Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities
- Restructuring to Reduce Workforce by More Than 50%, Maintaining Key Capabilities and Preserving Capital for New Programs
For earnings history and earnings-related data on Chimerix (CMRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Greene County Bancorp (GCBC) Tops Q3 EPS by 73c
- 1st Source Corp (SRCE) Tops Q3 EPS by 20c
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
